1-[(5-chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine (JNJ 7777120) is the first selective antagonist of the histamine H4 receptor. Johnson & Johnson Pharmaceutical Research and Development is developing JNJ 7777120 for the treatment of inflammatory disorders. JNJ 7777120 demonstrates efficacy as anti-inflammatory agents in vivo. JNJ 7777120 have shown promising activity in down-regulating immune responses in a range of animal disease models including acute inflammation, hapten-mediated colitis, allergic airway inflammation (e.g. allergic rhinitis), colitis, allergic pruritis and atopic dermatitis.